1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
3
|
Anwanwan D, Singh SK, Singh S, Saikam V
and Singh R: Challenges in liver cancer and possible treatment
approaches. Biochim Biophys Acta Rev Cancer. 1873:1883142020.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Mikhail S, Cosgrove D and Zeidan A:
Hepatocellular carcinoma: Systemic therapies and future
perspectives. Expert Rev Anticancer Ther. 14:1205–1218. 2014.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Jarroux J, Morillon A and Pinskaya M:
History, discovery, and classification of lncRNAs. Adv Exp Med
Biol. 1008:1–46. 2017. View Article : Google Scholar : PubMed/NCBI
|
6
|
Fatica A and Bozzoni I: Long non-coding
RNAs: New players in cell differentiation and development. Nat Rev
Genet. 15:7–21. 2014. View
Article : Google Scholar : PubMed/NCBI
|
7
|
Chen LL: Linking long noncoding RNA
localization and function. Trends Biochem Sci. 41:761–772. 2016.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Lim LJ, Wong SYS, Huang F, Lim S, Chong
SS, Ooi LL, Kon OL and Lee CG: Roles and regulation of long
noncoding RNAs in hepatocellular carcinoma. Cancer Res.
79:5131–5139. 2019. View Article : Google Scholar : PubMed/NCBI
|
9
|
Qin H, Zhenzhen Z and Quanbo L: Effect of
long intergenic non-coding RNA 238 on HBV replication and
expression in vitro. J Third Military Med Univ. 40:1942–1947.
2018.
|
10
|
Gao Q, Zhu H, Dong L, Shi W, Chen R, Song
Z, Huang C, Li J, Dong X, Zhou Y, et al: Integrated Proteogenomic
characterization of HBV-related hepatocellular carcinoma. Cell.
179:561–577.e22. 2019. View Article : Google Scholar : PubMed/NCBI
|
11
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
12
|
Ribatti D: The Chick Embryo
Chorioallantoic Membrane in the Study of Angiogenesis and
Metastasis. Springer; Netherlands: 2010, View Article : Google Scholar
|
13
|
Pinto MT, Ribeiro AS, Conde I, Carvalho R
and Paredes J: The chick chorioallantoic membrane model: A new in
vivo tool to evaluate breast cancer stem cell activity. Int J Mol
Sci. 22:3342020. View Article : Google Scholar : PubMed/NCBI
|
14
|
Zabielska K, Lechowski R, Król M,
Pawłowski KM, Motyl T, Dolka I and Zbikowski A: Derivation of
feline vaccine-associated fibrosarcoma cell line and its growth on
chick embryo chorioallantoic membrane-a new in vivo model for
veterinary oncological studies. Vet Res Commun. 36:227–233. 2012.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Cimpean AM, Lalosevic D, Lalosevic V,
Banovic P, Raica M and Mederle OA: Disodium Cromolyn and
Anti-podoplanin antibodies strongly inhibit growth of BHK
21/C13-derived Fibrosarcoma in a chick Embryo chorioallantoic
membrane model. In Vivo. 32:791–798. 2018. View Article : Google Scholar : PubMed/NCBI
|
16
|
Klingenberg M, Becker J, Eberth S, Kube D
and Wilting J: The chick chorioallantoic membrane as an in vivo
xenograft model for Burkitt lymphoma. BMC Cancer. 14:3392014.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Li M, Pathak RR, Lopez-Rivera E, Friedman
SL, Aguirre-Ghiso JA and Sikora AG: The In Ovo chick
chorioallantoic membrane (CAM) assay as an efficient Xenograft
model of hepatocellular carcinoma. J Vis Exp. 524112015.doi:
10.3791/52411. PubMed/NCBI
|
18
|
Avram S, Coricovac DE, Pavel IZ, Pinzaru
I, Ghiulai R, Baderca F, Soica C, Muntean D, Branisteanu DE,
Spandidos DA, et al: Standardization of A375 human melanoma models
on chicken embryo chorioallantoic membrane and Balb/c nude mice.
Oncol Rep. 38:89–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
19
|
Wilson SM and Chambers AF: Experimental
metastasis assays in the chick embryo. Curr Protoc Cell Biol.
Chapter 19: Unit 19.6. 2004.PubMed/NCBI
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Dash S, Balasubramaniam M, Dash C and
Pandhare J: Biotin-based Pulldown assay to validate mRNA targets of
cellular miRNAs. J Vis Exp. 577862018.doi: 10.3791/57786.
PubMed/NCBI
|
22
|
Zheng YL, Li L, Jia YX, Zhang BZ, Li JC,
Zhu YH, Li MQ, He JZ, Zeng TT, Ban XJ, et al: LINC01554-mediated
glucose metabolism reprogramming suppresses tumorigenicity in
hepatocellular carcinoma via downregulating PKM2 expression and
inhibiting Akt/mTOR signaling pathway. Theranostics. 9:796–810.
2019. View Article : Google Scholar : PubMed/NCBI
|
23
|
Ding Y, Sun Z, Zhang S, Chen Y, Zhou B, Li
G, Sun Q, Zhou D, Ge Y, Yan S and Wang W: Down-regulation of Long
Non-coding RNA LINC01554 in hepatocellular cancer and its clinical
significance. J Cancer. 11:3369–3374. 2020. View Article : Google Scholar : PubMed/NCBI
|
24
|
He J, Zuo Q, Hu B, Jin H, Wang C, Cheng Z,
Deng X, Yang C, Ruan H, Yu C, et al: A novel, liver-specific long
noncoding RNA LINC01093 suppresses HCC progression by interaction
with IGF2BP1 to facilitate decay of GLI1 mRNA. Cancer Lett.
450:98–109. 2019. View Article : Google Scholar : PubMed/NCBI
|
25
|
Zheng Y, Yu K, Huang C, Liu L, Zhao H, Huo
M and Zhang J: Integrated bioinformatics analysis reveals role of
the LINC01093/miR-96-5p/ZFAND5/NF-κB signaling axis in
hepatocellular carcinoma. Exp Ther Med. 18:3853–3860.
2019.PubMed/NCBI
|
26
|
Wang S, Xu M, Sun Z, Yu X, Deng Y and
Chang H: LINC01018 confers a novel tumor suppressor role in
hepatocellular carcinoma through sponging microRNA-182-5p. Am J
Physiol Gastrointest Liver Physiol. 317:G116–G126. 2019. View Article : Google Scholar : PubMed/NCBI
|
27
|
Wen Q, Wang D, Yang Y, Chen X, Pan X, Han
Q, Deng Y, Li X, Chen X, Yan J and Zhou J: Competing endogenous RNA
screening based on long noncoding RNA-messenger RNA co-expression
profile in Hepatitis B virus-associated hepatocarcinogenesis. J
Tradit Chin Med. 37:510–521. 2017. View Article : Google Scholar : PubMed/NCBI
|
28
|
Xie Y: Hepatitis B Virus-associated
hepatocellular carcinoma. Adv Exp Med Biol. 1018:11–21. 2017.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Jiang C, Li F, Yang M, Duan J, Lai J, Sun
S and Fan S: LINC00238 inhibits hepatic carcinoma progression by
activating TMEM106C-mediated apoptosis pathway. Mol Med Rep.
24:7572021. View Article : Google Scholar : PubMed/NCBI
|
30
|
Lin Y, Pan X and Shen HB: lncLocator 2.0:
A cell-line-specific subcellular localization predictor for long
non-coding RNAs with interpretable deep learning. Bioinformatics.
37:2308–2316. 2021. View Article : Google Scholar
|
31
|
Cao Z, Pan X, Yang Y, Huang Y and Shen HB:
The lncLocator: A subcellular localization predictor for long
non-coding RNAs based on a stacked ensemble classifier.
Bioinformatics. 34:2185–2194. 2018. View Article : Google Scholar : PubMed/NCBI
|
32
|
Zhang H, Yu C, Chen M, Li Z, Tian S, Jiang
J and Sun C: miR-522 contributes to cell proliferation of
hepatocellular carcinoma by targeting DKK1 and SFRP2. Tumour Biol.
37:11321–11329. 2016. View Article : Google Scholar : PubMed/NCBI
|
33
|
Li H, Han D, Hou Y, Chen H and Chen Z:
Statistical inference methods for two crossing survival curves: A
comparison of methods. PLoS One. 10:e01167742015. View Article : Google Scholar : PubMed/NCBI
|
34
|
Wang H, Huo X, Yang XR, He J, Cheng L,
Wang N, Deng X, Jin H, Wang N, Wang C, et al: STAT3-mediated
upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer
metastasis by regulating SOX4. Mol Cancer. 16:1362017. View Article : Google Scholar : PubMed/NCBI
|
35
|
Wang Y, Liu Z, Yao B, Li Q, Wang L, Wang
C, Dou C, Xu M, Liu Q and Tu K: Long non-coding RNA CASC2
suppresses epithelial-mesenchymal transition of hepatocellular
carcinoma cells through CASC2/miR-367/FBXW7 axis. Mol Cancer.
16:1232017. View Article : Google Scholar : PubMed/NCBI
|
36
|
Shi YH, Qi BB, Liu XB and Ding HM:
Upregulation of miR-522 is associated with poor outcome of
hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 20:3194–3198.
2016.PubMed/NCBI
|
37
|
Zhang T, Hu Y, Ju J, Hou L, Li Z, Xiao D,
Li Y, Yao J, Wang C, Zhang Y and Zhang L: Downregulation of miR-522
suppresses proliferation and metastasis of non-small cell lung
cancer cells by directly targeting DENN/MADD domain containing 2D.
Sci Rep. 6:193462016. View Article : Google Scholar : PubMed/NCBI
|
38
|
Umer M, Qureshi SA, Hashmi ZY, Raza A,
Ahmad J, Rahman M and Iqbal M: Promoter hypermethylation of Wnt
pathway inhibitors in hepatitis C virus-induced multistep
hepatocarcinogenesis. Virol J. 11:1172014. View Article : Google Scholar : PubMed/NCBI
|